APA

Lin P., Teng W., Jeng W., Hsieh Y., Hung C., Huang C., Lui K., Chen Y., Lin C., Lin C., Sheen I. & Lin S. (20210728). Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience. : European journal of gastroenterology & hepatology.

Chicago

Lin Po-Ting, Teng Wei, Jeng Wen-Juei, Hsieh Yi-Chung, Hung Chen-Fu, Huang Chien-Hao, Lui Kar-Wai, Chen Yi-Cheng, Lin Chen-Chun, Lin Chun-Yen, Sheen I-Shyan and Lin Shi-Ming. 20210728. Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience. : European journal of gastroenterology & hepatology.

Harvard

Lin P., Teng W., Jeng W., Hsieh Y., Hung C., Huang C., Lui K., Chen Y., Lin C., Lin C., Sheen I. and Lin S. (20210728). Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience. : European journal of gastroenterology & hepatology.

MLA

Lin Po-Ting, Teng Wei, Jeng Wen-Juei, Hsieh Yi-Chung, Hung Chen-Fu, Huang Chien-Hao, Lui Kar-Wai, Chen Yi-Cheng, Lin Chen-Chun, Lin Chun-Yen, Sheen I-Shyan and Lin Shi-Ming. Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience. : European journal of gastroenterology & hepatology. 20210728.